We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Shay Shemesh, MSc
201 614-3153
sshemesh@nuvectis.com
Diane Marsolini
201 627-8154
dmarsolini@nuvectis.com
Adenocarcinoma Ovarian Neoplasms Carcinoma, Ovarian Epithelial Carcinoma, Endometrioid Adenocarcinoma, Clear Cell Adenomyoepithelioma
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
This is in the inclusion criteria above
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Shay Shemesh, MSc
201 614-3153
sshemesh@nuvectis.com
Diane Marsolini
201 627-8154
dmarsolini@nuvectis.com
The study is sponsored by Nuvectis Pharma, Inc. and is in collaboration with Gynecologic Oncology Group Foundation; The European Network for Gynaecological Oncological Trial groups (ENGOT).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
